A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
This is an interventional, drug-drug interaction study to evaluate the effect of daily doses of Obicetrapib tablets on the pharmacokinetics of a combined oral contraceptive (COC), Drospirenone and Ethinyl Estradiol.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
NOVUM
Las Vegas, Nevada, United States
Maximum observed plasma concentration (Cmax) of COC
Plasma Cmax concentration of COC with and without Obicetrapib
Time frame: Upon completion of Treatment C (Day -6) and Treatments B+C (Day 12)
Area under the plasma concentration-time (AUC0-τ) curve for COC with and without coadministration with Obicetrapib
Plasma AUC0-τ for COC with and without coadministration of Obicetrapib
Time frame: Upon completion of Treatment C (Day -6) and Treatments B+C (Day 12)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.